Phase i study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

Investigational New Drugs

Volumn 33, Issue 5, 2015, Pages 1068-1077

  Doi, Toshihiko ^a   Yoshino, Takayuki ^a   Fuse, Nozomu ^a   Boku, Narikazu ^b,e   Yamazaki, Kentaro ^b   Koizumi, Wasaburo ^c   Shimada, Ken ^d,f   Takinishi, Yasutaka ^d   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

Author keywords

Colorectal cancer; FTD; Irinotecan; Phase I combination study; TAS 102; TPI

Indexed keywords

BEVACIZUMAB; FIRTECAN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TIPIRACIL PLUS TRIFLURIDINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; GLUCURONOSYLTRANSFERASE; KRAS PROTEIN, HUMAN; PROTEIN P21; TRIFLURIDINE; UGT1A1 ENZYME; URACIL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC COLORECTAL CANCER; MORNING DOSAGE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMATITIS; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG COMBINATION; GENETIC POLYMORPHISM; GENETICS; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); TRIFLURIDINE; URACIL;

EID: 84942082944     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0271-1     Document Type: Article

References (18)

1. Fujiwara Y, Heidelberger C (1970) Fluorinated pyrimidines. XXXVII. The incorporation of 5-trifluoromethyl-2′-deoxyuridine into the deoxyribonucleic acid vaccinia virus. Mol Pharmacol 6:281-291
2. Fujiwara Y, Oki T, Heidelberger C (1970) Fluorinated pyrimidines. XXXVII. Effect of 5-trifluoromethyl-2′-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol 6:273-280
3. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, Yamada Y, Asao T (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 59:1227-1236
4. Green MC, Pusztai L, Theriault LR, Adinin RB, Hofweber M, Fukushima M, Mita A, Bindra N, Hortobagyi GN (2006) Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol ASCO Annu Meet Proc Part I 24:10576
5. Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107:1383-1390
6. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL (2008) Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26:794-799
7. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL (2008) Phase 1 study of TAS-102 administered once daily on a five-day-per-week schedule in patients with solid tumors. Invest New Drugs 26:445-454
8. Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, Hironaka S, Koizumi W, Sasaki T (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107:429-434
9. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993-1001
10. Temmink OH, Hoebe EK, Fukushima M, Peters GJ (2007) Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 43:175-183
11. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13:545-549
12. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853-860
13. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499-508
14. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506
15. Mayer R, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909-1919
16. Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32:2319-2326
17. National Comprehensive Care Network. Clinical practiceguidelines in oncology (NCCN guidelines®). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp (accessed June 19, 2015)
18. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(suppl 3):iii1-iii9